Clinical Trial: Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06929325) titled 'Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors' on April 08.

Brief Summary: A randomized, double-blind, multicenter phase III clinical study to evaluate the efficacy and safety of sirolimus for injection (albumin-bound) combined with fulvestrant in patients with HR+ and HER2- advanced breast cancer.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: HR+/HER2- Advanced/Metastatic Breast Cancer

Intervention: DRUG: Sirolimus for Injection (Albumin-bound)

IV infusion, every 2 weeks, 4 weeks per t...